Therapeutic protein aggregation: mechanisms, design, and control
- PMID: 24908382
- PMCID: PMC4146573
- DOI: 10.1016/j.tibtech.2014.05.005
Therapeutic protein aggregation: mechanisms, design, and control
Abstract
Although it is well known that proteins are only marginally stable in their folded states, it is often less well appreciated that most proteins are inherently aggregation-prone in their unfolded or partially unfolded states, and the resulting aggregates can be extremely stable and long-lived. For therapeutic proteins, aggregates are a significant risk factor for deleterious immune responses in patients, and can form via a variety of mechanisms. Controlling aggregation using a mechanistic approach may allow improved design of therapeutic protein stability, as a complement to existing design strategies that target desired protein structures and function. Recent results highlight the importance of balancing protein environment with the inherent aggregation propensities of polypeptide chains.
Keywords: computational design; protein aggregation; protein interactions; protein stability.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Figures
References
-
- Mullard A. 2011 FDA drug approvals. Nat Rev Drug Discov. 2012;11:91–94. - PubMed
-
- Rob Aggarwal S. What's fueling the biotech engine-2012 to 2013. Nat Biotechnol. 2014;32:32–39. - PubMed
-
- Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm. 2005;289:1–30. - PubMed
-
- Wang W, et al. Aggregation of Therapeutic Proteins. John Wiley & Sons, Inc.; 2010.
-
- Jiskoot W, et al. Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci. 2012;101:946–954. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
